Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging.

IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Radionuclide Therapy Pub Date : 2023-06-20 DOI:10.4274/mirt.galenos.2022.72593

Jan Roczniak, Justyna Bączalska, Gabriela Kanclerz, Weronika Zielińska, Joanna Ożga, Błażej Cymerman, Agnieszka Stępień, Magdalena Kostkiewicz, Katarzyna Holcman

{"title":"Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging.","authors":"Jan Roczniak, Justyna Bączalska, Gabriela Kanclerz, Weronika Zielińska, Joanna Ożga, Błażej Cymerman, Agnieszka Stępień, Magdalena Kostkiewicz, Katarzyna Holcman","doi":"10.4274/mirt.galenos.2022.72593","DOIUrl":null,"url":null,"abstract":"Objectives: The pharmacological stress test with vasodilator agents is an alternative cardiological diagnostic tool for patients with contraindications to the classical stress test provided by physical activity during single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). The study compared the frequency of the side effects of regadenoson and dipyridamole during a SPECT MPI.Methods: This retrospective study included data of 283 consecutive patients who underwent pharmacological stress tests in years 2015-2020. The study group consisted of 240 patients who had received dipyridamole and 43 patients who had received regadenoson. The collected data included the patients' characteristics, the occurrence of side effects (divided into mild: headache, vertigo, nausea, vomiting, dyspnea, chest discomfort, hot flushes, general weakness and severe: bradycardia, hypotension, loss of consciousness), and blood pressure values/measurements.Results: Overall, complications occurred relatively often (regadenoson: 23.2%, dipirydamol: 26.7%, p=0.639). Procedure discontinuation was necessary in 0.7% of examinations, whereas pharmacological support was necessary in 4.7%. There was no difference in the prevalence of mild (regadenoson: 16.2%, dipirydamol: 18.3%, p=0.747) and severe complications (regadenoson: 11.6%, dipyridamole: 15.0%, p=0.563). However, regadenoson has been found to cause a significantly smaller mean decrease of systolic blood pressure (SBP) (regadenoson: -2.6±10.0 mmHg, dipyridamole: -8.7±9.6 mmHg, p=0.002), diastolic blood pressure (DBP) (regadenoson: -0.9±5.4 mmHg, dipyridamole: -3.6±6.2 mmHg, p=0.032), as well as mean arterial pressure (MAP) (regadenoson: -1.5±5.6 mmHg, dipyridamole: -5.4±6.5 mmHg, p=0.001).Conclusion: Regadenoson and dipyridamole presented a similar safety profile during SPECT MPI. However, regadenoson has been found to cause significantly smaller decreases in SBP, DBP, and MAP.","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e3/b9/MIRT-32-131.PMC10284185.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Radionuclide Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/mirt.galenos.2022.72593","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The pharmacological stress test with vasodilator agents is an alternative cardiological diagnostic tool for patients with contraindications to the classical stress test provided by physical activity during single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). The study compared the frequency of the side effects of regadenoson and dipyridamole during a SPECT MPI.

Methods: This retrospective study included data of 283 consecutive patients who underwent pharmacological stress tests in years 2015-2020. The study group consisted of 240 patients who had received dipyridamole and 43 patients who had received regadenoson. The collected data included the patients' characteristics, the occurrence of side effects (divided into mild: headache, vertigo, nausea, vomiting, dyspnea, chest discomfort, hot flushes, general weakness and severe: bradycardia, hypotension, loss of consciousness), and blood pressure values/measurements.

Results: Overall, complications occurred relatively often (regadenoson: 23.2%, dipirydamol: 26.7%, p=0.639). Procedure discontinuation was necessary in 0.7% of examinations, whereas pharmacological support was necessary in 4.7%. There was no difference in the prevalence of mild (regadenoson: 16.2%, dipirydamol: 18.3%, p=0.747) and severe complications (regadenoson: 11.6%, dipyridamole: 15.0%, p=0.563). However, regadenoson has been found to cause a significantly smaller mean decrease of systolic blood pressure (SBP) (regadenoson: -2.6±10.0 mmHg, dipyridamole: -8.7±9.6 mmHg, p=0.002), diastolic blood pressure (DBP) (regadenoson: -0.9±5.4 mmHg, dipyridamole: -3.6±6.2 mmHg, p=0.032), as well as mean arterial pressure (MAP) (regadenoson: -1.5±5.6 mmHg, dipyridamole: -5.4±6.5 mmHg, p=0.001).

Conclusion: Regadenoson and dipyridamole presented a similar safety profile during SPECT MPI. However, regadenoson has been found to cause significantly smaller decreases in SBP, DBP, and MAP.

Abstract Image

查看原文本刊更多论文

瑞腺苷松与双嘧达莫在应激心肌灌注显像中的安全性比较。

目的:在单光子发射计算机断层扫描(SPECT)心肌灌注成像(MPI)过程中，使用血管扩张剂进行药理学应激试验是对经典应激试验有禁忌症的患者的一种替代的心内科诊断工具。该研究比较了SPECT MPI期间瑞腺苷松和双嘧达莫的副作用频率。方法:本回顾性研究纳入了2015-2020年间连续接受药理学压力测试的283例患者的数据。研究组由240名接受双嘧达莫治疗的患者和43名接受瑞腺苷松治疗的患者组成。收集的资料包括患者的特征、副作用的发生情况(分为轻度:头痛、眩晕、恶心、呕吐、呼吸困难、胸部不适、潮热、全身无力和重度:心动过缓、低血压、意识丧失)和血压值/测量值。结果:总体而言，并发症发生率较高(瑞腺苷松:23.2%，双吡达摩:26.7%，p=0.639)。0.7%的检查需要中止手术，而4.7%的检查需要药物支持。轻度并发症发生率(regadenoson: 16.2%，双吡达摩:18.3%，p=0.747)和重度并发症发生率(regadenoson: 11.6%，双吡达摩:15.0%，p=0.563)差异无统计学意义。然而，regadenoson已被发现能显著降低收缩压(SBP) (regadenoson: -2.6±10.0 mmHg，双嘧达莫:-8.7±9.6 mmHg, p=0.002)、舒张压(DBP) (regadenoson: -0.9±5.4 mmHg，双嘧达莫:-3.6±6.2 mmHg, p=0.032)和平均动脉压(MAP) (regadenoson: -1.5±5.6 mmHg，双嘧达莫:-5.4±6.5 mmHg, p=0.001)。结论:瑞腺苷松和双嘧达莫在SPECT MPI中表现出相似的安全性。然而，已发现regadenoson引起的收缩压、舒张压和MAP的下降明显较小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging and Radionuclide Therapy RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) is publishes original research articles, invited reviews, editorials, short communications, letters, consensus statements, guidelines and case reports with a literature review on the topic, in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology.